Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v5-FR
Language French French
Date Updated 2023-03-17 2022-12-14
Drug Identification Number 02334860 02334860
Brand name NORDITROPIN NORDIFLEX NORDITROPIN NORDIFLEX
Common or Proper name NORDITROPIN NORDIFLEX NORDITROPIN NORDIFLEX
Company Name NOVO NORDISK CANADA INC NOVO NORDISK CANADA INC
Ingredients SOMATROPIN SOMATROPIN
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size EA EA
ATC code H01AC H01AC
ATC description ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2023-02-01 2023-02-01
Actual start date 2023-02-01
Estimated end date 2023-08-30 2023-08-30
Actual end date
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Norditropin® NordiFlex® 15 mg will continue to be available to Canadian patients to ensure all patients currently taking Norditropin® can remain on treatment. Norditropin® NordiFlex® 15 mg will continue to be available to Canadian patients to ensure all patients currently taking Norditropin® can remain on treatment.
Health Canada comments